Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

Blood

Volumn 98, Issue 13, 2001, Pages 3846-3848

  Moehler, Thomas M ^a   Neben, Kai ^a   Benner, Axel ^a   Egerer, Gerlinde ^a   Krasniqi, Fatime ^a   Ho, Anthony D ^a   Goldschmidt, Hartmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; THALIDOMIDE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEARING IMPAIRMENT; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NEPHROTOXICITY; NEURALGIA; PARESTHESIA; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; SALVAGE THERAPY; SOMNOLENCE; SURVIVAL TIME; THROMBOCYTOPENIA; TREMOR;

EID: 0035895104     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.13.3846     Document Type: Article

References (19)

1. Alexanian R, Dimopoulos M. The treament of multiple myeloma. N Engl J Med. 1994;330:484-489.
2. San Miguel JF, Blade JC, Garcia-Sanz R. Treatment of multiple myeloma. Haematologica. 1999;84:36-58.
3. Kyle RA. Diagnosis and management of multiple myeloma and related disorders. Prog Hematol. 1996;14:257-282.
4. Goldschmidt H, Hegenbart U, Wallmeier M. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Annal Oncol. 1997;8:243-246.
5. Singhal S, Metha J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
6. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Maim C. Frequent good partial remission from thalidomide including best response ever in patients with advanced refractory and relapsed multiple myeloma. Br J Haematol. 2000;108:229-2230.
7. Neben K, Moehler TM, Egerer G, Kraemer A, Hillengass J, Benner A, Ho AD, Goldschmidt H. High plasma basic fibroblast growth factor (bFGF) concentration is associated with good response to thalidomide monotherapy in progressive multiple myeloma [abstract]. Blood. 2000;101:124.
8. D'Amato RJ, Loughman MS, Flynn S, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
9. Munshi N, Desikan R, Zangari M, et al. Chemotherapy with DT-PACE for previously treated multiple myeloma [abstract]. Blood. 1999;94(suppl 1):123.
10. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
11. Moehler TM, Neben K, Hawighorst H, et al. Thalidomide and CED chemotherapy as salvage therapy in poor prognosis multiple myeloma [abstract]. Blood. 2000;101:290.
12. Blade J, Samson D, Reece D, et al. Criteria for definition of response, relapse and progression in multiple myeloma after high-dose therapy. Br J Haematol. 1998;102:1115-1123.
13. Kaplan EL and Meier P. Nonparametric estimation from incomplete observations, J Am Stat Assoc. 1958;53:457-481.
14. Dimopoulos MA, Delasalle KB, Champlin R, Alexanian R. Cyclophosphamide and etoposide therapy with GM-CSF for VAD resistant multiple myeloma. Br J Haematol. 1993;83:240-244.
15. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353-1356.
16. Miller HJ, Leong T, Khandekar JD, Greipp PR, Gertz MA, Kyle RA. Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study, Am J Clin Oncol. 1998;21:553-556.
17. Dimopoulos MA,Arbuck S, Huber M, et al. Primary therapy of multiple myeloma with paclitaxel (taxol). Ann Oncol. 1994;5:757-759.
18. Bonnet JD, Alexanian R, Salmon SE, Haut A, Dixon DO. Addition of cisplatin and bleomycin to vincristin-carmustine-doxorubicin-prednison (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a southwest oncology group study. Cancer Treat Rep. 1984;68:481-485.
19. Vesole DH, Crowley JJ, Catchaturian R, et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a southwest oncology group phase II trial. J Clin Oncol. 1999;17:2173-2179.